[
    [
        {
            "time": "",
            "original_text": "前三季营收净利润双增逾三成 安图生物股价为何年内‘腰斩’ 盈利能力下降",
            "features": {
                "keywords": [
                    "前三季",
                    "营收",
                    "净利润",
                    "安图生物",
                    "股价",
                    "腰斩",
                    "盈利能力",
                    "下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "前三季营收净利润双增逾三成 安图生物股价为何年内‘腰斩’ 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]